Boston Scientific (BSX) Payables (2009 - 2026)

Boston Scientific (BSX) has 18 years of Payables data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 13.65% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 13.65% YoY), and the FY2025 full-year result was $1.1 billion, up 19.17% from the prior year.
• Payables held at $1.1 billion in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $1.1 billion in Q4 2025 to a low of $696.0 million in Q1 2022.
• A 5-year average of $922.2 million and a median of $921.0 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables rose 24.71% in 2023 and slipped 2.37% in 2024, its largest moves.
• Tracing BSX's Payables over 5 years: stood at $862.0 million in 2022, then grew by 9.28% to $942.0 million in 2023, then gained by 1.91% to $960.0 million in 2024, then grew by 19.17% to $1.1 billion in 2025, then fell by 0.26% to $1.1 billion in 2026.
• Business Quant data shows BSX's Payables at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.